Table 3:
Multivariable models examining participant characteristics associated with serum urate goal achievement including treatment adherence as a covariate
| A. Participants with Missing Adherence Records Excluded (N=632) |
B. Non-adherence Imputed for Missing Adherence (N=764) |
|||
|---|---|---|---|---|
| Characteristic | Odds Ratio (95% CI) | P-value | Odds Ratio (95% CI) | P-value |
| DEMOGRAPHICS | ||||
| Age, per year | 1.05 (1.03, 1.08) | <0.001 | 1.04 (1.02, 1.07) | <0.001 |
| Male (vs. Female) | 0.00 (0.00, I) | 0.98 | 0.00 (0.00, I) | 0.98 |
| Race | 0.002 | <0.001 | ||
| White/Caucasian | Referent | Referent | ||
| Black/African American | 0.34 (0.19, 0.62) | 0.34 (0.20, 0.56) | ||
| Other | 0.74 (0.32, 1.70) | 0.50 (0.27, 0.95) | ||
| Education | 0.15 | 0.11 | ||
| High School or less | Referent | Referent | ||
| Some College or Associates Degree | 1.20 (0.66, 2.17) | 1.13 (0.68, 1.89) | ||
| Bachelor’s Degree or higher | 2.23 (1.08, 4.61) | 2.00 (1.09, 3.68) | ||
| Other/Not Stated | 1.32 (0.23, 7.45) | 1.31 (0.30, 5.66) | ||
| CORMOBIDITY & HEALTH FACTORS | ||||
| Chronic kidney disease – Stage III | 1.13 (0.65, 1.99) | 0.66 | 1.14 (0.70, 1.86) | 0.59 |
| Hypertension | 1.59 (0.83, 3.06) | 0.16 | 1.33 (0.78, 2.25) | 0.30 |
| Diabetes | 1.24 (0.69, 2.23) | 0.46 | 1.29 (0.78, 2.13) | 0.33 |
| Cardiovascular disease | 0.52 (0.28, 0.95) | 0.03 | 0.61 (0.36, 1.02) | 0.06 |
| Body mass index, kg/m2 | 0.33 | 0.77 | ||
| < 25 (healthy) | Referent | Referent | ||
| 25 ≤ BMI < 30 (overweight) | 0.63 (0.17, 2.39) | 0.83 (0.30, 2.32) | ||
| 30 ≤ BMI < 35 (obese) | 0.39 (0.11, 1.39) | 0.66 (0.24, 1.80) | ||
| ≥ 35 (morbidly obese) | 0.45 (0.13, 1.58) | 0.78 (0.29, 2.13) | ||
| EQ-5D-3L index, per 0.1 unit | 1.21 (1.08, 1.35) | 0.001 | 1.19 (1.08, 1.31) | <0.001 |
| GOUT RELATED FACTORS | ||||
| SU, per 1 mg/dl | 0.84 (0.70, 1.00) | 0.05 | 0.84 (0.73, 0.98) | 0.03 |
| Duration of gout, per 1 year | 0.99 (0.96, 1.01) | 0.22 | 0.98 (0.96, 1.00) | 0.06 |
| Presence of tophi | 0.21 (0.11, 0.39) | <0.001 | 0.29 (0.17, 0.49) | <0.001 |
| Prior allopurinol use | 0.99 (0.59, 1.68) | 0.98 | 1.06 (0.68, 1.66) | 0.80 |
| Diuretic use | 0.56 (0.31, 1.04) | 0.07 | 0.50 (0.30, 0.84) | 0.009 |
| Adherence (≥80% days taken) | 2.29 (1.05, 4.98) | 0.04 | 2.81 (1.82, 4.35) | <0.001 |
Abbreviations: I, infinity; BMI, body mass index; EQ-5D-3L, EuroQol 5 Dimension-3 Level; SU, serum urate; Model A excludes participants with missing pill count data in Phase 2; Model B includes all 764 participants from post-hoc analysis, imputing non-adherent status for all patients with Phase 2 missing pill count data; 2 records missing BMI covariate; SU goal < 6 mg/dl or < 5 mg/dl if tophi
C-statistics 0.79 (both models)